Alnylam Pharmaceuticals (ALNY) shares rallied 6% in the last trading session to close at $482.13. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the Biotech analysts here, and it's my pleasure to introduce ...
The most convenient way to use D2 is to just run it as a CLI executable to produce SVGs from .d2 files. You can run the install script with --dry-run to see the ...
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label ...
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM − Sustained Benefit of Vutrisiran Across Mortality, ...
Alnylam Pharmaceuticals ALNY is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for Onpattro to treat adult patients with ...
This Python package generates Tikz code for publication-ready vector graphics. Critical difference (CD) diagrams are a powerful tool to compare outcomes of multiple treatments over multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback